These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 21570056)

  • 1. Cystoid macular degeneration in exudative age-related macular degeneration.
    Querques G; Coscas F; Forte R; Massamba N; Sterkers M; Souied EH
    Am J Ophthalmol; 2011 Jul; 152(1):100-107.e2. PubMed ID: 21570056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pearl necklace sign: a novel spectral domain optical coherence tomography finding in exudative macular disease.
    Gelman SK; Freund KB; Shah VP; Sarraf D
    Retina; 2014 Oct; 34(10):2088-95. PubMed ID: 25020214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
    Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
    Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia.
    Carneiro AM; Silva RM; Veludo MJ; Barbosa A; Ruiz-Moreno JM; Falcão MS; Brandão EM; Falcão-Reis FM
    Ophthalmologica; 2011; 225(2):81-8. PubMed ID: 20881442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
    Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab.
    Barbazetto I; Saroj N; Shapiro H; Wong P; Freund KB
    Retina; 2010 Oct; 30(9):1376-85. PubMed ID: 20683380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab.
    Querques G; Querques L; Rafaeli O; Canoui-Poitrine F; Bandello F; Souied EH
    Invest Ophthalmol Vis Sci; 2011 Sep; 52(9):7012-8. PubMed ID: 21885622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.
    Schmidt-Erfurth U; Eldem B; Guymer R; Korobelnik JF; Schlingemann RO; Axer-Siegel R; Wiedemann P; Simader C; Gekkieva M; Weichselberger A;
    Ophthalmology; 2011 May; 118(5):831-9. PubMed ID: 21146229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.
    Sadda SR; Stoller G; Boyer DS; Blodi BA; Shapiro H; Ianchulev T
    Retina; 2010 Oct; 30(9):1390-9. PubMed ID: 20924261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitreomacular traction in a case of exudative age-related macular degeneration resistant to anti-VEGF therapy.
    Shah SU; Haller JA
    Acta Ophthalmol; 2012 Nov; 90(7):e569-70. PubMed ID: 22429537
    [No Abstract]   [Full Text] [Related]  

  • 12. Intravitreal methotrexate in therapeutically resistant exudative age-related macular degeneration.
    Kurup SK; Gee C; Greven CM
    Acta Ophthalmol; 2010 Jun; 88(4):e145-6. PubMed ID: 19681792
    [No Abstract]   [Full Text] [Related]  

  • 13. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.
    Rosenfeld PJ; Shapiro H; Tuomi L; Webster M; Elledge J; Blodi B;
    Ophthalmology; 2011 Mar; 118(3):523-30. PubMed ID: 20920825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resolution of retinal pigment epithelial detachment associated with exudative age-related macular degeneration following intravitreal ranibizumab therapy.
    Khetpal V; Heimmel MR; Rao SK; Scott IU; Greenberg PB
    Acta Ophthalmol; 2009 Feb; 87(1):115-6. PubMed ID: 18937807
    [No Abstract]   [Full Text] [Related]  

  • 15. Microperimetric changes after intravitreal bevacizumab for exudative age-related macular degeneration.
    Rensch F; Jonas JB
    Acta Ophthalmol; 2008 Sep; 86(6):696-7. PubMed ID: 18752522
    [No Abstract]   [Full Text] [Related]  

  • 16. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration.
    Gomi F; Sawa M; Tsujikawa M; Nishida K
    Retina; 2012 Oct; 32(9):1804-10. PubMed ID: 22718152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranibizumab for the treatment of exudative age-related macular degeneration associated with retinal pigment epithelial tear.
    Rouvas AA; Ladas ID; Georgalas I; Vergados I; Papakonstantinou D; Kotsolis AI
    Retina; 2011 Jun; 31(6):1083-8. PubMed ID: 21427630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy.
    Arias L; Caminal JM; Badia MB; Rubio MJ; Catala J; Pujol O
    Retina; 2010; 30(10):1601-8. PubMed ID: 21060271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined ranibizumab and photodynamic therapy to treat exudative age-related macular degeneration: an option for improving treatment efficiency.
    Mataix J; Palacios E; Carmen DM; Garcia-Pous M; Navea A
    Retina; 2010 Sep; 30(8):1190-6. PubMed ID: 20539256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of optical density ratios in subretinal fluid as a clinically relevant biomarker in exudative macular disease.
    Ahlers C; Golbaz I; Einwallner E; Dunavölgyi R; Malamos P; Stock G; Pruente C; Schmidt-Erfurth U
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3417-24. PubMed ID: 19168899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.